Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CPA3 | P15088 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.35 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7643175 | 0.79 | UTS2R (0.41) | CPA3 | |
| SCHEMBL3380508 | 0.77 | CPA3 (0.46) | CPA3NAALAD2KEAP1FFAR1FOLH1 | |
| SCHEMBL7645012 | 0.73 | OPRM1 (0.40) | HCAR3LTB4R | |
| SCHEMBL7647619 | 0.73 | HCAR3 (0.41) | HCAR3 | |
| SCHEMBL4155106 | 0.68 | CPA3 (0.47) | CPA3NAALAD2KEAP1FFAR1FOLH1 | |
| SCHEMBL6832509 | 0.67 | HTR1A (0.42) | CHRNB2CHRNB4CHRNA3CHRNA4CPA3 | |
| SCHEMBL7644468 | 0.67 | SLC1A3 (0.33) | CHRNB2CHRNB4CHRNA3CHRNA4CPA3 | |
| SCHEMBL7650063 | 0.67 | LCK (0.34) | CHRNB2CHRNB4CHRNA3CHRNA4CPA3 | |
| SCHEMBL11198448 | 0.66 | OPRK1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNA4CHRM2 | |
| SCHEMBL7647484 | 0.66 | KMT2A (0.38) | CPA3FFAR1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | CHRNB2 4263/4885CHRNB4 4099/4885CHRNA3 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.